BATM Advanced Communications Ltd (BVC) Fair Value & Analysis
Healthcare · GB · Market cap 44.9M GBX
Analysis
BATM Advanced Communications Ltd (BVC) currently trades at p0.1470, while our model-based Fair Value estimate is p0.1700 — implying the stock looks roughly 15.6% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
BATM Advanced Communications Ltd., together with its subsidiaries, engages in the development, production, and supply of real-time technologies and associated services in Israel, the United States, and Europe. It operates through four segments: Cyber, Networking, Diagnostics, and Non-core. The Cyber segment provides integrated hardware and software solutions for network encryption, including hardware security modules. The Networking segment engages in researching and developing, and marketing of data communication products, including Edgility, an open edge software platform that enables the deployment and life-cycle management of apps, and compute devices at the edge of the network; and a range of carrier grade products for switching and routing hardware and software products. The Diagnostics segment is involved in the development, sale, and distribution of in vitro diagnostics reagents and instruments, including proprietary products that focus on molecular diagnostics by test type …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.